SCHEMBL31015657

SCHEMBL31015657

CC1(C)OB(c2cncc(N3CCCC3)n2)OC1(C)C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 3/20 0.34
CYP11B1 P15538 4/20 0.33
CYP11B2 P19099 4/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
HTR1A P08908 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
CYP2C19 P33261 1/20 0.33
KMT2A Q03164 1/20 0.33
HSD17B10 Q99714 1/20 0.33
P2RX7 Q99572 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.31
FFAR4 Q5NUL3 1/20 0.31
HRH4 Q9H3N8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10137347 0.88 HRH4 (0.39) CYP11B1CYP11B2KDM4EALDH1A1CYP1A2
SCHEMBL10137342 0.88 KMT2A (0.37) CYP11B1CYP11B2KDM4EMEN1ALDH1A1
SCHEMBL12614839 0.80 ALDH1A1 (0.38) KDM4EMEN1ALDH1A1CYP1A2CYP3A4
SCHEMBL12616248 0.79 PDE10A (0.39) PDE10AKDM4E
SCHEMBL12731410 0.77 MAPT (0.36) ALDH1A1P2RX7SMN1; SMN2
SCHEMBL20043315 0.74 PIM2 (0.33) PDE10ACYP11B1CYP11B2KDM4EMEN1
SCHEMBL16437436 0.72 IRAK4 (0.36) P2RX7
SCHEMBL10169024 0.71 KMT2A (0.33) CYP11B1CYP11B2KDM4EMEN1ALDH1A1
SCHEMBL16866301 0.70 CDK2 (0.36) P2RX7
SCHEMBL1441832 0.70 CDK2 (0.36) P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2025-01-02 US disclosed
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors EPICS THERAPEUTICS (BE) 2024-09-17 US disclosed
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2024-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 PDE10A 3678/4885CYP11B1 3658/4885CYP11B2 4114/4885
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 PDE10A 3678/4885CYP11B1 3658/4885CYP11B2 4114/4885
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors METTL3, METTL16, DIMT1 PDE10A 3678/4885CYP11B1 3658/4885CYP11B2 4114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.